Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone L Gorter

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Postgraduate Medical Journal|May 19, 2012
Poor professionalism identified through investigation of unsolicited healthcare complaintsWalther N K A van Mook, Simone L Gorter, Wendy Kieboom, et al.
Rheumatology (Oxford, England)|June 17, 2015
Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Femke H M Prince, Maryanne Dijkstra, et al.
Rheumatology (Oxford, England)|February 1, 2011
An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children registerFemke H M Prince, Esther W de Bekker-Grob, Marinka Twilt, et al.
The Journal of Rheumatology|January 19, 2010
Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanerceptMarieke H Otten, Femke H M Prince, Marinka Twilt, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?Marieke H Otten, Femke H M Prince, Rebecca Ten Cate, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Postgraduate Medical Journal|May 19, 2012
Poor professionalism identified through investigation of unsolicited healthcare complaintsWalther N K A van Mook, Simone L Gorter, Wendy Kieboom, et al.
Rheumatology (Oxford, England)|June 17, 2015
Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Femke H M Prince, Maryanne Dijkstra, et al.
Rheumatology (Oxford, England)|February 1, 2011
An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children registerFemke H M Prince, Esther W de Bekker-Grob, Marinka Twilt, et al.
The Journal of Rheumatology|January 19, 2010
Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanerceptMarieke H Otten, Femke H M Prince, Marinka Twilt, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?Marieke H Otten, Femke H M Prince, Rebecca Ten Cate, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Pageof 3